Ultragenyx Pharmaceutical Inc.
NASDAQ:RAREBiotechnology
Healthcare
$17.22 +3.01%
+$0.81 today
- Market cap
- $1.76B
- Beta
- 0.38
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$6.06
52W Low $18.29High $42.37
Volume 3.12M
Average 1.81M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$466.00M
FY 2025 · Annual
Investing Cash Flow
$236.00M
FY 2025 · Annual
Financing Cash Flow
$478.00M
FY 2025 · Annual
+19.7% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (454.03M) | (707.42M) | (606.64M) | (569.18M) | (575M) |
| Depreciation & Amortization | 13.24M | 18.22M | 26.01M | 35.54M | 35M |
| Deferred Income Tax | 48.67M | 0 | (1.62M) | 0 | 0 |
| Stock-Based Compensation | 104.95M | 130.38M | 135.21M | 158.03M | 153M |
| Change in Working Capital | (63.24M) | 60.24M | (15.1M) | 13.92M | (23M) |
| Accounts Receivables | (5.43M) | (12.07M) | (22.78M) | (33.6M) | (31M) |
| Inventory | (3.12M) | (9.7M) | (6.93M) | (11.21M) | (6M) |
| Accounts Payables | 2.81M | 79.85M | 2.38M | 46.99M | 24M |
| Other Working Capital | (57.49M) | 2.16M | 12.23M | 11.73M | (10M) |
| Other Non-Cash Items | 11.71M | 118.12M | (12.67M) | (52.5M) | (56M) |
| Operating Cash Flow | (338.7M) | (380.47M) | (474.81M) | (414.19M) | (466M) |
| Capital Expenditures | (73.09M) | (146.12M) | (46.77M) | (7.49M) | (6M) |
| Acquisitions (Net) | 0 | (75.03M) | 0 | 0 | 0 |
| Purchases of Investments | (1.01B) | (614.74M) | (526.38M) | (408.61M) | (186M) |
| Sales of Investments | 890.85M | 545.08M | 746.2M | 413.27M | 444M |
| Other Investing Activities | (942K) | (30.84M) | (7.55M) | (14.94M) | (16M) |
| Investing Cash Flow | (195.37M) | (291.65M) | 168M | (17.77M) | 236M |
| Debt Repayment | 0 | 0 | 0 | 0 | 392M |
| Common Stock Issued | 78.94M | 0 | 379.76M | 380.98M | 86M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 39.61M | 501.21M | 8.39M | 18.26M | 0 |
| Financing Cash Flow | 118.55M | 501.21M | 388.14M | 399.24M | 478M |
| Effect of Forex Changes | (1.19M) | (1.08M) | 462K | (2.53M) | 5.47M |
| Net Change in Cash | (416.71M) | (171.98M) | 81.8M | (35.24M) | 253.47M |
| Free Cash Flow | (411.79M) | (526.59M) | (521.57M) | (421.68M) | (472M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$575.0M
+ D&A$35.0M
+ Stock-Based Comp$153.0M
+ Deferred Tax$0
- Working Capital-$23.0M
- Other Non-Cash-$56.0M
= Operating Cash Flow-$466.0M
- Capex-$6.0M
= Free Cash Flow-$472.0M
Analysis
FY2025 free cash flow is -$472.0M. FCF conversion is 82.1% of net income. Operating cash flow was -$466.0M, with capex of -$6.0M. The largest bridge item is Stock-Based Comp at $153.0M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 4, 2026 | |
| 8-K | Current report | Nov 3, 2026 | |
| SC 13G/A | SC 13G/A filing | Oct 30, 2026 |
Does RARE generate free cash flow?
Ultragenyx Pharmaceutical Inc. (RARE) generated -$472.00M of free cash flow in fiscal 2025.
How much operating cash flow does RARE produce?
Operating cash flow was -$466.00M, before capital expenditures of $6.00M.
Continue the stock analysis
Jump to another research area for this company.